Do analysts prefer PLUR or IMA?

ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts plainly believe ImageneBio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Which has preferable earnings and valuation, PLUR or IMA?

Pluri has higher revenue and earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.02M 12.83 -$23.82M -$2.45 N/A ImageneBio $800K 69.06 -$45.35M -$4.58 N/A

Is PLUR or IMA more profitable?

ImageneBio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,344.59% N/A -82.71% ImageneBio N/A -38.99% -34.84%

Does the media favor PLUR or IMA?

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PDSB or PLUR?

PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 992.37%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PDSB or PLUR more profitable?

PDS Biotechnology has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Pluri -2,344.59% N/A -82.71%

Does the media refer more to PDSB or PLUR?

In the previous week, PDS Biotechnology had 4 more articles in the media than Pluri. MarketBeat recorded 5 mentions for PDS Biotechnology and 1 mentions for Pluri. Pluri's average media sentiment score of 0.00 beat PDS Biotechnology's score of -0.11 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BKHA or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BKHA or PLUR?

Black Hawk Acquisition has higher earnings, but lower revenue than Pluri. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Pluri $1.02M 12.83 -$23.82M -$2.45 N/A

Is BKHA or PLUR more profitable?

Black Hawk Acquisition has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Pluri -2,344.59% N/A -82.71%

Does the media refer more to BKHA or PLUR?

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 1 articles in the media. Black Hawk Acquisition's average media sentiment score of 0.35 beat Pluri's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TIL or PLUR?

Instil Bio currently has a consensus target price of $7.00, indicating a potential downside of 3.31%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, TIL or PLUR?

Pluri has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Pluri $1.02M 12.83 -$23.82M -$2.45 N/A

Is TIL or PLUR more profitable?

Instil Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Pluri -2,344.59% N/A -82.71%

Do analysts prefer PLUR or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PLUR or APLM?

Apollomics has higher revenue and earnings than Pluri. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.02M 12.83 -$23.82M -$2.45 N/A Apollomics $8.50M 7.89 -$10.94M N/A N/A

Is PLUR or APLM more profitable?

Apollomics has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Company Net Margins Return on Equity Return on Assets Pluri -2,344.59% N/A -82.71% Apollomics N/A N/A N/A

Pluri (PLUR) Competitors

$1.06 -0.04 (-3.64%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$1.03 -0.03 (-2.45%)

As of 09/23/2026 05:37 PM Eastern

Compare

PLUR vs. IMA, PDSB, BKHA, TIL, and APLM

Should you buy Pluri stock or one of its competitors? Pluri's main competitors and comparable companies include ImageneBio (IMA), PDS Biotechnology (PDSB), Black Hawk Acquisition (BKHA), Instil Bio (TIL), and Apollomics (APLM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pluri compare to ImageneBio?

Pluri (NASDAQ:PLUR) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts plainly believe ImageneBio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Pluri has higher revenue and earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	12.83	-$23.82M	-$2.45	N/A
ImageneBio	$800K	69.06	-$45.35M	-$4.58	N/A

ImageneBio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
ImageneBio	N/A	-38.99%	-34.84%

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pluri has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

ImageneBio beats Pluri on 9 of the 15 factors compared between the two stocks.

How does Pluri compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

PDS Biotechnology has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Pluri	-2,344.59%	N/A	-82.71%

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, PDS Biotechnology had 4 more articles in the media than Pluri. MarketBeat recorded 5 mentions for PDS Biotechnology and 1 mentions for Pluri. Pluri's average media sentiment score of 0.00 beat PDS Biotechnology's score of -0.11 indicating that Pluri is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 992.37%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pluri has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Pluri	$1.02M	12.83	-$23.82M	-$2.45	N/A

PDS Biotechnology has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Summary

PDS Biotechnology beats Pluri on 8 of the 15 factors compared between the two stocks.

How does Pluri compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Black Hawk Acquisition has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

16.6% of Pluri shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Black Hawk Acquisition has higher earnings, but lower revenue than Pluri.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Pluri	$1.02M	12.83	-$23.82M	-$2.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Pluri	-2,344.59%	N/A	-82.71%

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 1 articles in the media. Black Hawk Acquisition's average media sentiment score of 0.35 beat Pluri's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pluri beats Black Hawk Acquisition on 4 of the 7 factors compared between the two stocks.

How does Pluri compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Pluri had 1 more articles in the media than Instil Bio. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.

Company	Overall Sentiment
Instil Bio	Neutral
Pluri	Neutral

Instil Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Pluri	-2,344.59%	N/A	-82.71%

Instil Bio currently has a consensus target price of $7.00, indicating a potential downside of 3.31%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pluri has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Pluri	$1.02M	12.83	-$23.82M	-$2.45	N/A

Summary

Instil Bio beats Pluri on 7 of the 13 factors compared between the two stocks.

How does Pluri compare to Apollomics?

Pluri (NASDAQ:PLUR) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Pluri had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Apollomics. Pluri's average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
Pluri	Neutral
Apollomics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pluri has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Apollomics has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Apollomics	N/A	N/A	N/A

16.6% of Pluri shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Apollomics has higher revenue and earnings than Pluri.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	12.83	-$23.82M	-$2.45	N/A
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A

Summary

Apollomics beats Pluri on 6 of the 9 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.58M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.43	13.88	274.02	25.69
Price / Sales	12.83	1,311.41	633.28	76.04
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-0.65	15.30	10.44	6.32
Net Income	-$23.82M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-1.85%	-1.71%	-0.66%	0.17%
1 Month Performance	-32.05%	-6.17%	-3.16%	-3.27%
1 Year Performance	-76.34%	30.64%	15.15%	5.58%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.2505 of 5 stars	$1.06 -3.6%	N/A	-77.4%	$13.58M	$1.02M	N/A	113
IMA ImageneBio	3.0943 of 5 stars	$5.03 +2.1%	$29.00 +477.1%	-38.8%	$57.02M	$800K	N/A	70	Gap Up
PDSB PDS Biotechnology	2.4109 of 5 stars	$0.96 +63.7%	$9.00 +839.5%	-21.5%	$53.90M	N/A	N/A	20	Gap Down High Trading Volume
BKHA Black Hawk Acquisition	N/A	$11.99 0.0%	N/A	+9.0%	$49.74M	N/A	N/A	N/A
TIL Instil Bio	0.7127 of 5 stars	$7.32 +1.5%	$7.00 -4.3%	-59.0%	$49.60M	N/A	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors